clinical trial · NCT04658199
A Study to Test the Safety and Tolerability of Long-term UCB0107 Administration in Study Participants With Progressive Supranuclear Palsy
UCB Biopharma SRL·phase1·active not recruiting·n = 19
Progressive Supranuclear PalsyUCB0107 (bepranemab)
brief summary
The purpose of the study is to assess the long-term safety and tolerability of UCB0107 in study participants with progressive supranuclear palsy (PSP).
started
Nov 16, 2020
primary completion
Dec 13, 2027
completion
Dec 13, 2027
last updated
Jul 29, 2025
official title
An Open-Label Extension Study to Evaluate the Safety and Tolerability of Long-Term UCB0107 Administration in Study Participants With Progressive Supranuclear Palsy
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol